Document is current

Article History

First Online: 30 November 2019

Compliance with Ethical Standards

:

: The present study was conducted in accordance with the Helsinki Declaration of 1975, as revised in 1983, on Ethical Principles for Medical Research Involving Human Subjects and after approval by the local ethical committee of each University clinic. All eligible patients provided written informed consent.

: No funding was received for this study.

: A Chiricozzi has served as an advisory board member and consultant, and has received fees and speaker’s honoraria or has participated in clinical trials for Abbvie, Biogen, Fresenius Kabi, LEO-Pharma, Eli-Lilly, Novartis, UCB-Pharma, Sanofi, and Janssen. A. Conti has served as an advisory board member and consultant and has received fees, honoraria, or has participated in clinical trials for Abbvie, Eli-Lilly, Janssen Cilag, LEO-Pharma, Novartis, Pfizer, UCB-Pharma, Wyeth, Sandoz, and Schering Plough. C. De Simone served as an advisory board member and consultant and has received speaker’s honoraria from Abbvie, MSD, Allmiral, Pfizer, Leo Pharma, Lilly, Novartis, UCB-Pharma, Sanofi, Janssen, and Celgene. P. Malagoli has been a scientific consultant/speaker/clinical study investigator for AbbVie, Amgen, Biogen, Celgene, Janssen, LEO-Pharma, Eli-Lilly, and Novartis. A. Balato has been a scientific consultant/speaker/clinical study investigator for AbbVie, Celgene, Janssen, Eli-Lilly, Novartis, Pfizer, Sanofi, and UCB-Pharma. M. Burlando, G. Caldarola, G. Damiani, V. Dini, F. Peccerillo, C. Potenza, E. Scala, and N. Skroza declare no conflicts of interest.